ADmit Therapeutics
Barcelona, ES · 3 known investors
ADmit Therapeutics develops the MAP-AD® test, a blood biomarker-based diagnostic tool that predicts progression from mild cognitive impairment to Alzheimer's disease dementia for patients with neurodegenerative diseases. The company operates as a certified clinical laboratory serving healthcare providers and researchers in precision medicine.
Investors · 3
Frequently asked questions
- What does ADmit Therapeutics do?
- ADmit Therapeutics develops the MAP-AD® test, a blood biomarker-based diagnostic tool that predicts progression from mild cognitive impairment to Alzheimer's disease dementia for patients with neurodegenerative diseases. The company operates as a certified clinical laboratory serving healthcare providers and researchers in precision medicine.
- Who are ADmit Therapeutics's investors?
- ADmit Therapeutics's investors include BStartup, Ship2B, WA4STEAM.
- Where is ADmit Therapeutics headquartered?
- ADmit Therapeutics is headquartered in Barcelona, ES.